Fungal Nail Infections (Onychomycosis): A Never-Ending Story?

PLoS Pathogens

Volumn 10, Issue 6, 2014, Pages

  Ghannoum, Mahmoud ^a   Isham, Nancy ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; CICLOPIROX; DODECYL 2 N,N DIMETHYLAMINOPROPIONATE HYDROCHLORIDE; FLUCONAZOLE; ITRACONAZOLE; NAIL LACQUER; PAINT; TAVABOROLE; TERBINAFINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL (TOPIC); CONIDIUM; DIABETES MELLITUS; DIABETIC FOOT; DISEASE PREDISPOSITION; DRUG PENETRATION; EPIDERMOPHYTON; FOOT ULCER; FUSARIUM; GENETIC TRAIT; HUMAN; IMMUNE DEFICIENCY; IONTOPHORESIS; LOW LEVEL LASER THERAPY; MICROSPORUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ONYCHOMYCOSIS; PERIPHERAL CIRCULATION; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RISK FACTOR; TINEA CORPORIS; TINEA PEDIS; TOENAIL ONYCHOMYCOSIS; TRICHOPHYTON; TRICHOPHYTON RUBRUM; ULTRASOUND THERAPY; AGE; DISEASE CARRIER; DRUG ADMINISTRATION; DRUG EFFECTS; FOOT DERMATOSES; FUNGUS SPORE; GROWTH, DEVELOPMENT AND AGING; HAND DERMATOSES; INCIDENCE; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; PREVALENCE; RECURRENT DISEASE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; AGE FACTORS; ANTIFUNGAL AGENTS; DISEASE RESERVOIRS; DRUG ADMINISTRATION SCHEDULE; EPIDERMOPHYTON; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; INCIDENCE; MICROSPORUM; ONYCHOMYCOSIS; PREVALENCE; RECURRENCE; RISK FACTORS; SPORES, FUNGAL; TRICHOPHYTON;

EID: 84903444567     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004105     Document Type: Article

References (32)

1. Havlickova A, Czaika VA, Friedrich M, (2008) Epidemiological trends in skin mycoses worldwide. Mycoses 51 S4: 2-15.
2. Haneke E, Roseeuw D, (1999) The scope of onychomycosis: epidemiology and clinical features. Int J Dermatol 38 (Suppl 2):: 7-12.
3. Ogasawara Y, (2003) Prevalence and patient's consciousness of tinea pedis and onychomycosis. Nihon Ishinkin Gakkai Zasshi 44: 253-260.
4. Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, et al. (2000) A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 43: 641-648.
5. Scher RK, (1994) Onychomycosis is more than a cosmetic problem. Br J Dermatol 130: 15.
6. Gupta AK, Jain HC, Lynde CW, MacDonald P, Cooper EA, et al. (2000) Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 43: 244-248.
7. Faergemann J, Correia O, Nowicki R, Ro BI, (2005) Genetic predisposition- understanding underlying mechanisms of onychomycosis. J Eur Acad Dermatol Venerol 19: 17-19.
8. Lanternier F, Pathan S, Vincent QB, Liu L, Cypowyj S, et al, (2013) Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med 369: 1704-1714.
9. Saunte DM, Holgersen JB, Haedersdal M, Strauss G, Bitsch M, et al. (2006) Prevalence of toe nail onychomycosis in diabetic patients. Acta Derm Venerol 86: 425-428.
10. Nenoff P, Ginter-Hanselmayer G, Tietz HJ, (2012) Fungal nail infections- an update: Part 1- Prevalence, epidemiology, predisposing conditions, and differential diagnosis. Hautarzt 63: 30-38.
11. Scher RK, Baran R, (2003) Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 149: 5-9.
12. Arrese JE, Pierard-Franchimont C, Pierard GE, (1996) Fatal hyalohyphomycosis following Fusarium onychomycosis in an immunocompromised patient. Am J Dermatopathol 18: 196-198.
13. Aly R, (1994) Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 31: S21.
14. Ghannoum MA, Mukherjee PK, Warshaw EM, Evans S, Korman NJ, et al. (2013) Molecular analysis of dermatophytes suggest spread of infection among household members. Cutis 91: 237-246.
15. Elewski B, Tavakkol A, (2005) Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag 1: 299-306.
16. Tosti A, Piraccini BM, Lorenzi S, (2000) Onychomycosis caused by nondermatophyte molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 42: 217-224.
17. BlueCross BlueShield of Northeastern New York (2006 November 28) Drug Therapy Guidelines: Antifungal Agents Lamisil (terbinafine), Sporanox (itraconazole), Penlac (ciclopirox), Vfend (voriconazole). Drug P&T Newsletter.
18. Lauharanta J, (1992) Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 17: 41-43.
19. Ghannoum MA, Long L, Pfister WR, (2009) Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model. Mycoses 52: 35-43.
20. Faergemann J, Zehender H, Millerioux L, (1994) Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 19: 121-126.
21. Osborne CS, Leitner I, Favre B, Ryder NS, (2004) Antifungal drug response in an in vitro model of dermatophyte nail infection. Med Mycol 42: 159-163.
22. Ghannoum M, Isham N, Herbert J, Henry W, Yurdakul S, (2011) Activity of TDT 067 (Terbinafine in Transfersome) against Agents of Onychomycosis, as Determined by Minimum Inhibitory and Fungicidal Concentrations. J Clin Microbiol 49: 1716-1720.
23. Alley MR, Baker SJ, Beutner KR, Plattner J, (2007) Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs 16: 157-167.
24. Ghannoum M, Isham N, Catalano V, (2013) A Second Look at Efficacy Criteria for Onychomycosis: Clinical and Mycological Cure. Br J Dermatol. E-pub ahead of print. doi:10.1111/bjd.12594.
25. Gupta AK, Simpson FC, (2013) Laser therapy for onychomycosis. J Cutan Med Surg 17: 301-307.
26. Harris F, Pierpoint L, (2012) Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent. Med Res Rev 32: 1292-1327.
27. Delgado-Charro MB, (2012) Iontophoretic drug delivery across the nail. Expert Opin Drug Deliv 9: 91-103.
28. Silva JL, Doimo G, Faria DP, (2011) The use of high frequency waves to treat onychomycosis: preliminary communication of three cases. An Bras Dermatol 86: 598-600.
29. Abadi D, Zderic V, (2011) Ultrasound-mediated nail drug delivery system. J Ultrasound Med 30: 1723-1730.
30. Yazdanparast SA, Barton RC, (2006) Arthroconidia production in Trichophyton rubrum and a new ex vivo model of onychomycosis. J Med Microbiol 55: 1577-1581.
31. Bradley M, Leidich S, Isham N, Elewski B, Ghannoum M, (1999) Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail. Mycoses 42: 105-110.
32. Ghannoum MA, Isham N, Long L, (2012) Optimization of an infected shoe model for the evaluation of an ultraviolet shoe sanitizer device. J Am Podiatr Med Assoc 102: 309-313.